HS Codes for Pharmaceuticals & Medicines

Can I ship medicines from Portugal to other countries?

Shipping finished medicaments internationally requires a Marketing Authorisation in the destination country. Within the EU, a centrally-authorised medicine (EMA approval) or nationally-authorised medicine can move between EU member states under certain conditions. Outside the EU (UK, USA, etc.), separate national authorisations are required. Personal use quantities may be exempt under some countries' personal importation policies, but commercial export always requires proper authorisation.

What is the HS code for vitamin supplements?

It depends on how the product is presented and labelled. Vitamin supplements presented as food (nutritional supplement with nutritional claims) are generally classified under Chapter 21 (9021.90.00 or 2106.90.xx). Vitamins presented as medicaments (making therapeutic claims) fall under Chapter 30 (3004.50.90). The packaging, labelling and intended use determine the classification — customs authorities in the destination country will examine the product's claims.

Do I need a special licence to export medicines from Portugal?

Yes — commercial export of medicinal products from Portugal requires a wholesale distribution authorisation from INFARMED (Portuguese national medicines and health products authority) and the medicine must hold a valid Marketing Authorisation in the destination country. For export outside the EU, a Certificate of a Pharmaceutical Product (CPP) from INFARMED may be required by the destination country's authorities.

What HS code covers COVID-19 test kits?

Rapid antigen COVID-19 test kits are classified under HS 3822 (diagnostic reagents). Specifically, lateral flow test kits typically use HS 3822.11.00 (diagnostic reagents on a backing). These are classified as IVD (in-vitro diagnostic) medical devices and require CE IVD marking for EU market access under EU Regulation 2017/746.

Are there import duties on pharmaceuticals in the EU?

No — virtually all Chapter 30 pharmaceutical products attract 0% MFN import duty in the EU under the WTO Pharmaceutical Tariff Elimination Agreement. The regulatory barrier (Marketing Authorisation) is the primary constraint on pharmaceutical trade, not import duties.

How do I find the correct HS code for a pharmaceutical product?

Use the EU TARIC database (ec.europa.eu/taxation_customs/dds2/taric) and browse Chapter 30. Key headings: 3002 (blood fractions, vaccines, diagnostics), 3004 (finished dose form medicaments — the most common heading for commercial medicines), 3005 (wound care dressings), 3006 (pharmaceutical accessories, sterile surgical supplies). The distinction between a medicament (Chapter 30) and a food supplement (Chapter 21) or cosmetic (Chapter 33) is determined by the product's regulatory approval status and the claims made on its label. For borderline products, request a Binding Tariff Information (BTI) ruling from your national customs authority.

What happens if pharmaceutical products are declared under the wrong HS code?

Pharmaceutical misclassification has regulatory consequences beyond duty. Declaring a pharmaceutical product under a food HS code (Chapter 21) to avoid the Marketing Authorisation requirement is regulatory fraud — customs and medicines authorities cross-reference HS codes against product descriptions and claims. A product mis-declared as a food supplement when it legally requires a Medicine Licence may be seized as an unregistered medicament at border inspection posts. This is particularly relevant for herbal remedies, nutraceuticals and products combining nutritional and medicinal active components. For duty, Chapter 30 is 0% so financial impact of duty error is nil — regulatory risk dominates.

How does country of origin affect pharmaceutical trade?

Country of origin matters for pharmaceuticals primarily in Intellectual Property and trade agreement contexts rather than import duty (which is 0% globally for Chapter 30 under the WTO Pharmaceutical Tariff Elimination Agreement). The EU maintains strong patent protection — generic equivalents of patented medicines cannot be imported regardless of origin until the EU patent expires. For Generic medicines: EU-India trade negotiations include significant pharmaceutical IP provisions. For biosimilars: EU EMA requires separate clinical data for each biosimilar regardless of manufacturing country. Country of manufacture on packaging must accurately reflect the GMP-certified manufacturing site.

How does the EU-UK TCA affect pharmaceutical trade between EU and UK?

Under the EU-UK TCA, pharmaceutical mutual recognition provisions allow information exchange between EMA (EU) and MHRA (UK) on GMP inspections. However, regulatory divergence is the dominant post-Brexit challenge: EU Marketing Authorisations are no longer valid in the UK, and MHRA authorisations are not valid in the EU — each medicine requires separate approval in each jurisdiction. Batch testing, which previously needed to be done only once in the EU for acceptance in the UK, now requires UK-specific batch release testing for UK distribution. This significantly increased costs for cross-Channel pharmaceutical supply chains and led many companies to restructure EU-UK product dossiers.

What import licences or permits are required for pharmaceutical imports?

Pharmaceutical imports require both regulatory authorisation and, for certain categories, explicit import permits. EU requirements: Marketing Authorisation from EMA or national authority (INFARMED in Portugal) for all finished medicaments placed on the EU market; controlled drug import licences from INFARMED for narcotics and psychotropics (Schedule I–IV). USA requirements: FDA NDA (New Drug Application) or ANDA (Abbreviated NDA for generics) for finished drugs; DEA Schedule I–V licence for controlled substances. For vaccines: specific import authorisations from national authorities. These requirements apply regardless of the 0% customs duty — regulatory gating, not tariff rates, governs pharmaceutical trade.

What is the difference between 6-digit, 8-digit and 10-digit HS codes for pharmaceuticals?

The 6-digit HS code for most finished medicines is 3004.90 (other medicaments). EU CN8 extends to 8 digits (e.g., 3004.90.19 or 3004.90.90) depending on the specific formulation. TARIC 10-digit adds EU-specific measures. The WTO Pharmaceutical Tariff Elimination Agreement lists specific pharmaceutical products at 6-digit level that attract 0% duty in signatory countries — confirming correct 6-digit classification ensures the 0% rate applies. For IVD medical devices (heading 3822), sub-codes distinguish diagnostic types and are important for CE IVD compliance determination.

How should I declare pharmaceutical products on a commercial invoice?

A pharmaceutical commercial invoice must include: HS code (e.g., 3004.20.00 for antibiotics), INN (International Non-proprietary Name) or active ingredient name and strength, dosage form (tablets, ampoules, vials, patches), quantity in units/packs and total weight, declared value, country of manufacture (for GMP audit trail), batch number and expiry date, Marketing Authorisation number in the destination country, temperature storage requirements, and for controlled substances the import permit number issued by the national drugs authority. Missing any of these fields on a pharmaceutical invoice causes border inspection post delays.

Can I import prescription medicines for personal use internationally?

Personal importation of prescription medicines is governed by the destination country's policy. The USA FDA Personal Importation Policy allows import of up to a 90-day personal supply, provided the medicine poses no unreasonable risk and is not commercially available in the USA. In the EU, individuals can carry personal-use medicines across internal EU borders under free movement provisions. For courier shipments from non-EU to EU: amounts consistent with personal use (typically 30–90 day supply, addressed to a named patient) generally clear under personal exemption, but controlled substances (opioids, benzodiazepines, stimulants) require prior import permits from INFARMED or the equivalent national drugs authority even for personal quantities.

What is Binding Tariff Information (BTI) for pharmaceutical products?

BTI is a legally binding 3-year HS classification ruling from EU customs authorities. For pharmaceuticals, BTI is valuable when: a product sits on the boundary between a medicament (Chapter 30) and a food supplement (Chapter 21) or medical device (Chapter 90); a novel biological product does not fit neatly into existing headings; or a combination drug-device product has disputed classification. A BTI resolves the HS classification question but does not resolve the regulatory status question — a separate INFARMED or EMA classification opinion is needed to confirm whether a product requires a Marketing Authorisation. Apply through Portugal's AT (Autoridade Tributária e Aduaneira).

How does the classification of a product as a drug versus food supplement affect customs and shipping?

Classification as a drug (Chapter 30) versus food supplement (Chapter 21) has profound effects beyond HS codes: regulatory approval requirements (Marketing Authorisation vs food notification), import controls (border inspection post examination for drugs), carrier handling procedures, and labelling obligations all differ. Customs authorities examine product labels and ingredient lists — a product claiming to 'treat' or 'cure' a condition is likely a drug; one offering 'nutritional support' is likely a supplement. This is particularly relevant for herbal remedies, nutraceuticals and products combining food ingredients with plant extracts that have known pharmacological activity. Importers of borderline products should obtain a formal classification opinion from the national medicines authority (INFARMED in Portugal) before commercial shipments begin.